[vc_row][vc_column][vc_column_text].
.
.
Cancer Vaccine Research:
Unique Immuno-Oncology Research Solutions to Discover and
Validate Biomarkers in Predicting Cancer Vaccine Candidates.
Tumor Microenvironment Analysis: OncoPeptTUME
High-Throughput NGS Pipeline
Insights Beyond IHC / FACS
No Human Analysis Bias
Analyze Immune, Stromal & Epithelial Cells
Less Tissue Material Required
Neo-Epitope Prioritization Analysis: OncoPeptVAC
Identify, Predict and Prioritize Vaccine Candidates
Compatible With Any Tumor Model
Combines Proprietary TCR Binding Prediction with HLA
Binding for Better Accuracy
2 Week Turnaround Time
 |
MedGenome’s OncoPeptTUME and OncoPeptVAC provides immune phenotyping and analysis of potential biomarkers to determine potential success of checkpoint inhibitors. In order to predict response to treatment, over 4,000 expression data sets are validated using over 1,500 pure cell type expression data sets. This information is then combined with active inflammatory pathways. . Request two brochures: |
[wpforms id=”1264″]
